pro inflammatory cytokines

Can Pro Inflammatory Cytokines be Targeted for Cancer Therapy?

Yes, targeting pro inflammatory cytokines holds promise as a therapeutic strategy in cancer treatment. Various approaches are being explored, including the use of monoclonal antibodies, small molecule inhibitors, and cytokine antagonists. For instance, TNF inhibitors such as infliximab and etanercept are being investigated for their potential to reduce tumor growth and improve patient outcomes. Additionally, IL-6 inhibitors like tocilizumab have shown efficacy in treating certain cancers and reducing inflammation-associated symptoms.

Frequently asked queries:

Partnered Content Networks

Relevant Topics